Nov 20 (Reuters) – The US Food and Drug Administration declined to approve Capricor Therapeutics’ experimental cell therapy for a fatal inherited disease that weakens muscle, the health regulator said on Friday, adding to a string of regulatory setbacks for the biotech firm. Capricor, whose shares fell 77% in extended trading, did not immediately respond […]
Health
US FDA declines to approve Capricor’s Duchenne treatment citing unreliable trial data; shares slump
Audio By Carbonatix
Nov 20 (Reuters) – The US Food and Drug Administration declined to approve Capricor Therapeutics’ experimental cell therapy for a fatal inherited disease that weakens muscle, the health regulator said on Friday, adding to a string of regulatory setbacks for the biotech firm.
Capricor, whose shares fell 77% in extended trading, did not immediately respond to a Reuters request for comment.
The company was seeking approval for the therapy, known as deramiocel, to preserve upper-limb function in Duchenne muscular dystrophy patients.
The agency said serious data integrity problems in a key clinical trial, including unauthorized changes to the analysis plan after it began, violations of rules meant to keep patients and researchers from knowing who got the treatment, and other protocol violations.
The FDA said the violations “compromise the reliability of the study data.” It added that the data is “not considered reliable or interpretable” as proof that the treatment works. It also said the treatment did not meet the study’s main goals.
Duchenne is a fatal genetic disease that primarily affects boys and causes progressive muscle weakness, loss of mobility, heart complications and premature death.
The regulatory rejection deals a heavy blow to Capricor, threatening its lead experimental asset and clouding the company’s commercial prospects after months of efforts to salvage the application by narrowing its focus to arm and hand movement.
The decision follows a nine-to-three vote in July in which the FDA’s advisers said the evidence presented at the time did not establish deramiocel’s effectiveness in Duchenne-related heart disease.
In August, Capricor had submitted an amended application with 24-month data from its late-stage study, along with extra analyses, focusing specifically on upper-limb muscle function.
(Reporting by Kunal Das, Sahil Pandey and Kamal Choudhury in Bengaluru. Editing by Alan Barona and Perla Velasco)

